Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
A phase 2 trial of Sirolimus protein-bound particles in metastatic cancer, run by Aadi Bioscience, Inc., active and no longer recruiting.
Overview
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) is a phase 2 interventional study registered as NCT05103358 by Aadi Bioscience, Inc., with 120 participants planned, started 2022-02-15 and due to reach its primary completion in 2024-12-31. Interventions recorded: nab-sirolimus. Conditions listed: Tumor, Tumor, Solid, Metastasis, Metastatic Cancer. No results are recorded here; the registry entry is the source.
Setting
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes.
Phase
Phase 2
Sponsor
Aadi Bioscience, Inc.
Registry
Enrolled
120